Gilead Shares Surge 1.93% on $910M Volume, Climb to 120th in Daily Trading Rankings

On October 3, 2025, Gilead Sciences (GILD) rose 1.93% with a trading volume of $0.91 billion, ranking 120th among stocks by daily trading value. The biopharmaceutical giant's performance followed a strategic update highlighting expanded clinical trials for its antiviral therapies targeting emerging viral strains. The company announced partnerships with two academic research institutions to accelerate data collection for its next-generation HIV treatment pipeline, which analysts noted could strengthen long-term revenue visibility.

Recent regulatory developments also contributed to investor sentiment. The FDA extended its review period for Gilead's novel hepatitis C treatment by 60 days, citing the need for additional safety data analysis. While this delay initially triggered caution, market participants interpreted the action as a procedural step rather than a rejection signal, given the drug's strong Phase III efficacy results. Institutional buying activity intensified in the afternoon session, with multiple large-cap fund managers increasing their exposure to the stock ahead of Q3 earnings reports.

To run this test accurately I need to pin down a few practical details: 1. Universe definition • Do you want to include every common stock listed on NYSE + NASDAQ (+ AMEX), or only a specific index (e.g., the Russell 3000)? • Should ADRs, ETFs, SPACs, OTC and micro-caps be excluded? 2. Portfolio construction • Equal-weight across the 500 names each day, or value-weight by their traded dollar volume? • Assume zero transaction costs, or would you like to include commissions/slippage? 3. Benchmark / performance metrics • Any particular benchmark (e.g., SPY) you want shown alongside? • Key statistics beyond total return & annualized Sharpe (e.g., max drawdown)? Once I have this, I can generate the daily stock list, build the 1-day-hold portfolio, and run the back-test from 2022-01-03 (first trading day of 2022) through today.